CL2015002713A1 - Métodos para mejorar la calidad de la composición del meibo de las glándulas de meibomio. - Google Patents

Métodos para mejorar la calidad de la composición del meibo de las glándulas de meibomio.

Info

Publication number
CL2015002713A1
CL2015002713A1 CL2015002713A CL2015002713A CL2015002713A1 CL 2015002713 A1 CL2015002713 A1 CL 2015002713A1 CL 2015002713 A CL2015002713 A CL 2015002713A CL 2015002713 A CL2015002713 A CL 2015002713A CL 2015002713 A1 CL2015002713 A1 CL 2015002713A1
Authority
CL
Chile
Prior art keywords
meibo
composition
quality
improve
methods
Prior art date
Application number
CL2015002713A
Other languages
English (en)
Inventor
S Gregory Smith
Michael B Gross
Olav E Sandnes
Original Assignee
Physicians Recommended Nutriceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49947054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002713(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Physicians Recommended Nutriceuticals Llc filed Critical Physicians Recommended Nutriceuticals Llc
Publication of CL2015002713A1 publication Critical patent/CL2015002713A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ACIDOS GRASOS OMEGA-3 PARA EL MEJORAMIENTO DE LA CANTIDAD DE LA COMPOSICIÓN DEL MEIBO DE LAS GLANDULAS MEIBOMIANAS INFLAMADAS O DISFUNCIONALES DE UN MAMIFERO, PER MEDIO DE SU ADMINISTRACION EN UNA CANTIDAD EFECTIVA DE ENTRE 600 MG Y 5000 MG CON EL FIN DE FACILITAR UN INCREMENTO DE LOS NIVELES DE OMEGA-3 ANTIINFLAMATORIO Y DISMINUIR LOS NIVELES DE OMEGA-6 INFLAMATORIO EN LA COMPOSICION DEL MEIBO.
CL2015002713A 2013-03-12 2015-09-14 Métodos para mejorar la calidad de la composición del meibo de las glándulas de meibomio. CL2015002713A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/815,599 US9381183B2 (en) 2012-07-18 2013-03-12 Methods for improving the quality of the meibum composition of meibomian glands

Publications (1)

Publication Number Publication Date
CL2015002713A1 true CL2015002713A1 (es) 2016-09-30

Family

ID=49947054

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002713A CL2015002713A1 (es) 2013-03-12 2015-09-14 Métodos para mejorar la calidad de la composición del meibo de las glándulas de meibomio.

Country Status (10)

Country Link
US (1) US9381183B2 (es)
EP (1) EP2968243B1 (es)
JP (2) JP6538022B2 (es)
KR (1) KR101904850B1 (es)
CN (1) CN105358142A (es)
CA (1) CA2904737C (es)
CL (1) CL2015002713A1 (es)
ES (1) ES2743614T3 (es)
PE (1) PE20160123A1 (es)
WO (1) WO2014158356A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US9115078B2 (en) * 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
MX2014002877A (es) 2011-09-12 2014-09-12 Tassos Georgiou Uso de acidos grasos omega para el tratamiento de enfermedades.
JP6324671B2 (ja) * 2012-06-19 2018-05-16 参天製薬株式会社 ヘアレス動物の眼瞼状態の変化方法
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
JP6497812B2 (ja) * 2013-06-28 2019-04-10 学校法人慶應義塾 マイボーム腺機能不全の処置剤
AU2015269353B2 (en) * 2014-06-04 2020-03-26 Tersus Pharmaceuticals, LLC Methods of treating chronic dry eye disease using C16:1n7 palmitoleate and derivatives thereof
WO2018005685A1 (en) * 2016-06-29 2018-01-04 Physicians Recommended Nutriceuticals, Llc Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用
WO2021148845A1 (en) * 2020-01-23 2021-07-29 Visufarma S.P.A. Ophthalmic composition for the treatment of dry eye disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
MXPA02004703A (es) 1999-11-09 2004-09-10 Alcon Inc Composiciones que contienen derivados de acido hidroxieicostetraenoico y metodos de uso para tratar trastornos de resequedad en los ojos.
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US20060127505A1 (en) 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US6649195B1 (en) 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
US7041840B2 (en) 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
RU2007103835A (ru) * 2004-07-01 2008-08-10 Шепенс Ай Рисерч (Us) Композиции и способы лечения заболеваний и нарушений состояния глаз
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
DE202004015931U1 (de) 2004-10-13 2005-01-05 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung
EP1962618A2 (en) 2005-12-20 2008-09-03 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
WO2008143642A2 (en) 2006-11-09 2008-11-27 Children's Medical Center Corporation Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids
EP1932520A1 (en) 2006-12-15 2008-06-18 Novartis AG Nutritional supplement composition for treatment of ocular diseases
EP1932521A1 (en) 2006-12-15 2008-06-18 Novartis AG Nutritional supplement composition for treatment of ocular diseases
US20090226547A1 (en) 2008-03-05 2009-09-10 Gilbard Jeffrey P Dietary Supplement For Eye Health
EP2349233A4 (en) 2008-10-09 2012-04-18 Waratah Pharmaceuticals Inc USE OF SCYLLO-INOSITOLS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH MACULAR DEGENERATION
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
JP2013510095A (ja) * 2009-11-06 2013-03-21 アルコン リサーチ， リミテッド ドライアイの軽減のための栄養サプリメント
KR20120115380A (ko) * 2010-01-11 2012-10-17 지티엑스, 인코포레이티드 마이봄선 기능 장애의 치료 방법
EP2641597A4 (en) * 2010-11-19 2014-04-30 Nippon Suisan Kaisha Ltd THERAPEUTIC OR PROPHYLACTIC AGENT FOR CORNEAL EPITHELIUM DISORDERS AND / OR CONNECTIVE EPITHELIUM DISORDERS
CA2738357C (en) 2011-04-07 2019-08-06 Amerisciences, Lp Methods and compositions to promote ocular health

Also Published As

Publication number Publication date
JP6538022B2 (ja) 2019-07-03
PE20160123A1 (es) 2016-03-03
ES2743614T3 (es) 2020-02-20
US20140024625A1 (en) 2014-01-23
EP2968243A4 (en) 2016-09-14
JP2016512245A (ja) 2016-04-25
KR101904850B1 (ko) 2018-10-08
WO2014158356A1 (en) 2014-10-02
EP2968243A1 (en) 2016-01-20
US9381183B2 (en) 2016-07-05
JP2019058194A (ja) 2019-04-18
EP2968243B1 (en) 2019-06-19
CA2904737C (en) 2019-11-26
CA2904737A1 (en) 2014-10-02
KR20150126405A (ko) 2015-11-11
CN105358142A (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
CL2015002713A1 (es) Métodos para mejorar la calidad de la composición del meibo de las glándulas de meibomio.
CR20160154A (es) Ácidos grasos octanoico, nonanoico y decanoico con un adulticida piretroide
BR112016014508A2 (pt) Lipídeo compreendendo ácidos graxos poli- insaturados de cadeia longa
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
ES2637421T3 (es) Composiciones tópicas que comprenden variantes de pliegue-OB
GT201700138A (es) Pirazolpiridinaminas
SA515361092B1 (ar) تركيبات راسكادوتريل الدهنية
AR105190A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
EA201791885A1 (ru) Смесь жирных кислот и её применение для лечения воспалительных патологий
ES2666322T3 (es) Composiciones farmacéuticas para el tratamiento de trastornos musculares
CL2016002400A1 (es) Formulación para higiene personal
JP2016519101A5 (es)
CL2016001350A1 (es) Composiciones de ketoprofeno de accion prologanda.
CL2017001773A1 (es) Análogos de calcitonina para tratar enfermedades y trastornos.
DOP2017000142A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
AR099863A1 (es) Método para reducir el riesgo de hipersensibilidad al dolor visceral
CL2016003131A1 (es) Composiciones de omega-3, formas de dosis, y métodos de uso
CR20180456A (es) Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
AR095937A1 (es) Potenciador de la solubilidad en agua a base de glucógeno
PL3006027T3 (pl) Kompozycje zawierające aminokwasy do stosowania w leczeniu ogólnoustrojowego stanu zapalnego związanego z udarem u pacjentów z dysfagią
AR102545A1 (es) Suplementos nutricionales que contienen un componente peptídico y método de protección contra la obesidad
FR3009955B1 (fr) Composition a base d'acide gras polyinsature et de vitamine d destinee a une administration par voie orale pour ameliorer la qualite de la chevelure
MX358901B (es) Fluidos dielectricos de alto punto de inflamabilidad, baja viscosidad, basados en trigliceridos.